But, as Stephen O'Rahilly, director of the Metabolic Research Laboratories at the University of Cambridge in the UK, points out, Symlin (pramlintide) is already approved and is “used by a lot of ...

Liraglutide (NN2211) is a GLP-1 receptor agonist that is administered by a single daily injection. As with pramlintide and exenatide, nausea is the most common adverse effect associated with ...

Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement ...

It works by activating amylin and calcitonin receptors which activates signals ... (apart from the old and not really good one called pramlintide/Symlin), and the most advanced is Novo Nordisk ...

And pramlintide, a synthetic version of the pancreatic hormone amylin, promotes the sensation of feeling full. Now, scientists such as Dixon are investigating a third potential hormonal medication ...

an amylin analog that is currently in phase IIb development. The two companies will co-develop and co-commercialize petrelintide and combination products, including a fixed-dose combination of ...

As part of the deal, the companies will work together to develop Zealand’s amylin analog as a foundational therapy for weight management as well as Roche’s petrelintide and CT-388, which are GLP-1/GIP ...

The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and co-commercialize Zealand Pharma’s long-acting amylin analog ... s GLP-1/GIP receptor agonist ...